Entereg Documents Offer Detailed Insight Into REMS Review Process

GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.